Dyadic International, Inc. - DYAI EV/Sales Multiple

Public company logo of Dyadic International (DYAI)

Dyadic International (DYAI) leverages C1 patents to reduce protein synthesis costs. On GURU.Markets, the EV/Sales valuation exhibits sideways movement, with the metric standing at 3847.90, which may mask downside risks. The company generates revenue by licensing its fungal platform for the agricultural sector and vaccines, while the stable management under Mark Emalfarb focuses on expanding partnerships with pharmaceutical behemoths.

DYAI: Dyadic International Inc EV/Sales Multiple 11/23/2025 - 11/19/2026

Financial and market metric breakdowns for Dyadic International, Inc. (DYAI)

- price and consensus price forecast:
Fundamental company valuation:DYAI (Dyadic)
Manufactured product of dyadic.com

Investors are assessing the potential of Dyadic International (DYAI) through the Enterprise Value to revenue ratio, which allows for the measurement of the asset's market price inclusive of net debt without distortions from the capital structure. By analyzing the business valuation via EV/Sales, one can understand how the C1 platform patents and the low demand elasticity for R&D acceleration support the company's high valuation relative to its current sales.